SLC6A2 and attention deficit-hyperactivity disorder: It is now approved as a novel nonstimulant medication for the treatment of ADHD, with norepinephrine transporter inhibition, serotonin receptor modulations, and indirect dopamine enhancement properties.12 Recently, several large randomized clinical trials (RCTs)13,14,15,16 have reported that viloxazine shows significant efficacy compared with placebo in treating ADHD in children and adolescents, and it also has relatively good tolerability.